Investments
271Portfolio Exits
59Partners & Customers
2Service Providers
3About Novo Holdings
Novo Holdings is the holding company of the Novo Group and manages the investment assets of the Novo Nordisk Foundation. It invests in life science companies at all stages of development and in a broad portfolio of equity and fixed-income securities. Novo Holdings was formerly known as Novo. The company was founded in 1999 and is based in Hellerup, Denmark.
Latest Novo Holdings News
Dec 7, 2023
Photo: Doctor Anywhere 07 December, 2023 Singapore-based healthcare company Doctor Anywhere (DA) has raised $40.8 million in a Series C1 extension round from investors including Square Peg and Novo Holdings, according to an announcement on Thursday. In Dec 2022, the firm had raised a Series C1 funding round of $38.8 million, led by Novo Holdings and backed by existing shareholders including Asia Partners, Kamet Capital, Square Peg, IHH Healthcare, EDBI, and OSK-SBI Venture Partners. The Series C1 round came after the healthtech startup raised a $65.7 million Series C in August 2021. The funds from the latest financing will be used to drive next-generation healthcare innovation within the company, and to deepen its presence in secondary care. The company will intensify product innovation in building a vertically integrated digital healthcare ecosystem. This ecosystem will cater to the rising demand for healthcare services.
Novo Holdings Investments
271 Investments
Novo Holdings has made 271 investments. Their latest investment was in Doctor Anywhere as part of their Series C - III on December 12, 2023.
Novo Holdings Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
12/6/2023 | Series C - III | Doctor Anywhere | $40.8M | No | Square Peg Ventures, and Undisclosed Investors | 2 |
12/4/2023 | Unattributed | energyRe | Yes | Glentra Capital, and PKA | 2 | |
11/15/2023 | Series B | NMD Pharma | $80M | No | 3 | |
11/2/2023 | Series B | |||||
10/11/2023 | Series D |
Date | 12/6/2023 | 12/4/2023 | 11/15/2023 | 11/2/2023 | 10/11/2023 |
|---|---|---|---|---|---|
Round | Series C - III | Unattributed | Series B | Series B | Series D |
Company | Doctor Anywhere | energyRe | NMD Pharma | ||
Amount | $40.8M | $80M | |||
New? | No | Yes | No | ||
Co-Investors | Square Peg Ventures, and Undisclosed Investors | Glentra Capital, and PKA | |||
Sources | 2 | 2 | 3 |
Novo Holdings Portfolio Exits
59 Portfolio Exits
Novo Holdings has 59 portfolio exits. Their latest portfolio exit was Altasciences Clinical Research on September 21, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
9/21/2023 | Divestiture | 2 | |||
2/9/2023 | Reverse Merger | 4 | |||
12/29/2022 | Reverse Merger | 5 | |||
Date | 9/21/2023 | 2/9/2023 | 12/29/2022 | ||
|---|---|---|---|---|---|
Exit | Divestiture | Reverse Merger | Reverse Merger | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 2 | 4 | 5 |
Novo Holdings Acquisitions
13 Acquisitions
Novo Holdings acquired 13 companies. Their latest acquisition was Paratek Pharmaceuticals on September 20, 2023.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
9/20/2023 | Debt | $129.3M | Take Private | 10 | ||
6/21/2023 | Acquired | 10 | ||||
9/23/2022 | Other | Acquired | 1 | |||
1/4/2022 | ||||||
1/3/2022 |
Date | 9/20/2023 | 6/21/2023 | 9/23/2022 | 1/4/2022 | 1/3/2022 |
|---|---|---|---|---|---|
Investment Stage | Debt | Other | |||
Companies | |||||
Valuation | |||||
Total Funding | $129.3M | ||||
Note | Take Private | Acquired | Acquired | ||
Sources | 10 | 10 | 1 |
Novo Holdings Partners & Customers
2 Partners and customers
Novo Holdings has 2 strategic partners and customers. Novo Holdings recently partnered with Industriens Pension, Urban Partners, and DSB Ejendomme on February 2, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
2/7/2023 | Partner | Denmark | Novo Holdings · Four partners agree to jointly redevelop Jernbanebyen in Copenhagen DSB , NREP , Industriens Pension and Novo Holdings have entered into a joint venture agreement to redevelop Jernbanebyen in Copenhagen . | 2 | |
11/19/2019 | Partner |
Date | 2/7/2023 | 11/19/2019 |
|---|---|---|
Type | Partner | Partner |
Business Partner | ||
Country | Denmark | |
News Snippet | Novo Holdings · Four partners agree to jointly redevelop Jernbanebyen in Copenhagen DSB , NREP , Industriens Pension and Novo Holdings have entered into a joint venture agreement to redevelop Jernbanebyen in Copenhagen . | |
Sources | 2 |
Novo Holdings Service Providers
5 Service Providers
Novo Holdings has 5 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acquired - II | Counsel | General Counsel | |
Service Provider | |||
|---|---|---|---|
Associated Rounds | Acquired - II | ||
Provider Type | Counsel | ||
Service Type | General Counsel |
Partnership data by VentureSource
Novo Holdings Team
16 Team Members
Novo Holdings has 16 team members, including current Chief Executive Officer, Kasim Kutay.
Name | Work History | Title | Status |
|---|---|---|---|
Kasim Kutay | Chief Executive Officer | Current | |
Name | Kasim Kutay | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer | ||||
Status | Current |
Compare Novo Holdings to Competitors
Alexandra Instituttet is an information technology consultant and developer. It provides artificial intelligence, digital green transition, cyber security, digital health, and more. It was founded in 1999 and is based in Aarhus, Denmark.
Luminary is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with cell engineering to overcome antigen escape and T-cell dysfunction. Its therapeutic solutions include BAFF CAR-T, Universal Receptor, and a non-viral allogeneic platform. The company was founded in 2019 and is based in Minneapolis, Minnesota.
Gilboa Therapeutics operates as a preclinical-stage biopharmaceutical. It focuses on the development of novel, next-generation cancer immunotherapies designed to harness the power of a patient’s own immune system to treat cancer and improve outcomes. The company was founded in 2020 and is based in Rehovot, Israel.
Healios is a company focused on digital health, specifically within the neurology and clinical trials sectors. The company offers a digital health platform that utilizes digital biomarkers and remote monitoring to improve research for new treatments in neuroscience. These digital tools, such as smartphone and wearable devices, measure and collect health information, providing precise and objective measurements over long periods of time, primarily for the benefit of the clinical research and patient monitoring industries. It was founded in 2012 and is based in Basel, Switzerland.
Immunwork is a pharmaceutical company that focuses on the research, development, and commercialization of new drugs based on its technology platform for treating multiple types of cancer, autoimmune diseases, osteoporosis, and other severe clinical conditions.
Kelvin Health is a company that operates in the healthcare sector, with a focus on leveraging artificial intelligence for health diagnostics. The company offers an intelligent solution for the detection and monitoring of various abnormalities and inflammation processes, using AI analysis applied to digital thermal imaging. This service is primarily targeted towards specialists in the healthcare industry. It was founded in 2020 and is based in Sofia, Bulgaria.
Loading...